Ryo Sugiura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ryo Sugiura has a total of 185 co-authors. Here are the top co-authors by number of shared publications:
- Masaki Kuwatani
Department of Gastroenterology and Hepatology Hokkaido University Hospital Sapporo Hokkaido Japan
22 shared publications Naoya Sakamoto
Hokkaido University Hospital, Japan
18 shared publications- Naoya Sakamoto
Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan
11 shared publications - Kazumichi Kawakubo
Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan
10 shared publications Kazumichi Kawakubo
Hokkaido University Hospital, Japan
8 shared publicationsYoshiya Yamamoto
Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan
7 shared publications
Latest Publications
- 26 October 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
A Case With Longitudinal Changes in Apolipoprotein A2 Isoform Indices Associated With CA19‐9 and MRI Findings Until Pancreatic Cancer Development
An 80‐year‐old female was referred to our hospital 6 years earlier with an abnormal plasma apolipoprotein A2 isoform (ApoA2‐i) index, which is a promising biomarker for pancreatic cancer. Endoscopic ultrasonography (EUS) revealed a single small cystic lesion in the pancreatic head. Subsequently, the patient was followed up regularly. Two years after the initial visit, her ApoA2‐i index was 50.2 μg/mL, and her plasma CA19‐9 level was 42.5 U/mL. Magnetic resonance cholangiopancreatography (MRCP) performed 3 years after the initial visit also demonstrated small cystic lesions in the pancreatic head, consistent with the findings of the initial EUS, and a signal defect in the main pancreatic duct (MPD) in the pancreatic body, with a normal upstream MPD diameter. Her ApoA2‐i index was 52.4 μg/mL, and her plasma CA19‐9 level was 42.0 U/mL. Follow‐up MRCP indicated similar cystic lesions in the pancreatic head and a signal defect in the MPD in the pancreatic body, with a normal upstream MPD diameter. However, her serial ApoA2‐i indices gradually decreased from 52.1 to 35.7 μg/mL, correlated with an increase in plasma CA19‐9. The latest MRCP demonstrated a similar signal defect and dilatation of the upstream MPD diameter compared with the previous MPD diameters. Her ApoA2‐i index slightly decreased to 35.2 μg/mL, whereas her CA19‐9 level remarkably increased to 1320 U/mL. Endoscopic retrograde pancreatography with cytology demonstrated adenocarcinoma cells. In the present case, we observed longitudinal changes in ApoA2‐i indices correlated with CA19‐9 and MRCP findings.
- 26 October 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
A Case With Longitudinal Changes in Apolipoprotein A2 Isoform Indices Associated With CA19‐9 and MRI Findings Until Pancreatic Cancer Development
An 80‐year‐old female was referred to our hospital 6 years earlier with an abnormal plasma apolipoprotein A2 isoform (ApoA2‐i) index, which is a promising biomarker for pancreatic cancer. Endoscopic ultrasonography (EUS) revealed a single small cystic lesion in the pancreatic head. Subsequently, the patient was followed up regularly. Two years after the initial visit, her ApoA2‐i index was 50.2 μg/mL, and her plasma CA19‐9 level was 42.5 U/mL. Magnetic resonance cholangiopancreatography (MRCP) performed 3 years after the initial visit also demonstrated small cystic lesions in the pancreatic head, consistent with the findings of the initial EUS, and a signal defect in the main pancreatic duct (MPD) in the pancreatic body, with a normal upstream MPD diameter. Her ApoA2‐i index was 52.4 μg/mL, and her plasma CA19‐9 level was 42.0 U/mL. Follow‐up MRCP indicated similar cystic lesions in the pancreatic head and a signal defect in the MPD in the pancreatic body, with a normal upstream MPD diameter. However, her serial ApoA2‐i indices gradually decreased from 52.1 to 35.7 μg/mL, correlated with an increase in plasma CA19‐9. The latest MRCP demonstrated a similar signal defect and dilatation of the upstream MPD diameter compared with the previous MPD diameters. Her ApoA2‐i index slightly decreased to 35.2 μg/mL, whereas her CA19‐9 level remarkably increased to 1320 U/mL. Endoscopic retrograde pancreatography with cytology demonstrated adenocarcinoma cells. In the present case, we observed longitudinal changes in ApoA2‐i indices correlated with CA19‐9 and MRCP findings.
- Open Access
- 1 October 2026
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 58 (S 05) , E1090-E1092
Two-step transjejunal biliary drainage using a colonoscope and an oblique-viewing linear-array echoendoscope after pancreatoduodenectomy
- 1 October 2026
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 58 (S 05) , E1090-E1092
Open AccessTwo-step transjejunal biliary drainage using a colonoscope and an oblique-viewing linear-array echoendoscope after pancreatoduodenectomy
- 3 August 2026
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
Endoscopic Ultrasonography for Diagnosing Common Bile Duct Stones With Negative Initial Imaging: A Multicenter Prospective Exploratory Study
Background: Common bile duct stones (CBDSs) can cause severe conditions. Endoscopic retrograde cholangiopancreatography (ERCP) is recommended but has a high rate of adverse events. However, some suspected cases do not have stones, requiring accurate evaluation in even high‐likelihood patients. Endoscopic ultrasonography (EUS) offers high diagnostic performance. This study aimed to clarify the utility of EUS for diagnosing CBDSs in patients with strong suspicion of CBDSs. Methods: This multicenter prospective exploratory study included patients with a high likelihood of CBDSs according to the American Society of Gastrointestinal Endoscopy guidelines, in whom CBDSs were not detected on initial imaging. EUS was subsequently performed, and diagnostic performance was assessed using ERCP findings or clinical course. Results: Forty‐eight patients were analyzed. EUS identified CBDSs in 21 and no stones in 27. A final diagnosis of CBDS was confirmed in 19 patients. The accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of EUS (95% confidence interval) were 95.8% (85.7%–99.5%), 100% (75.1%–100%), 93.1% (77.2%–99.2%), 90.5% (69.6%–98.8%), and 100% (81.7%–100%). Among patients without CBDSs at final diagnosis, unnecessary ERCP was avoided in 79.3%. Conclusions: EUS would accurately diagnose CBDSs in high‐likelihood patients with negative initial imaging, potentially reducing unnecessary ERCPs.
- 3 August 2026
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
Endoscopic Ultrasonography for Diagnosing Common Bile Duct Stones With Negative Initial Imaging: A Multicenter Prospective Exploratory Study
Background: Common bile duct stones (CBDSs) can cause severe conditions. Endoscopic retrograde cholangiopancreatography (ERCP) is recommended but has a high rate of adverse events. However, some suspected cases do not have stones, requiring accurate evaluation in even high‐likelihood patients. Endoscopic ultrasonography (EUS) offers high diagnostic performance. This study aimed to clarify the utility of EUS for diagnosing CBDSs in patients with strong suspicion of CBDSs. Methods: This multicenter prospective exploratory study included patients with a high likelihood of CBDSs according to the American Society of Gastrointestinal Endoscopy guidelines, in whom CBDSs were not detected on initial imaging. EUS was subsequently performed, and diagnostic performance was assessed using ERCP findings or clinical course. Results: Forty‐eight patients were analyzed. EUS identified CBDSs in 21 and no stones in 27. A final diagnosis of CBDS was confirmed in 19 patients. The accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of EUS (95% confidence interval) were 95.8% (85.7%–99.5%), 100% (75.1%–100%), 93.1% (77.2%–99.2%), 90.5% (69.6%–98.8%), and 100% (81.7%–100%). Among patients without CBDSs at final diagnosis, unnecessary ERCP was avoided in 79.3%. Conclusions: EUS would accurately diagnose CBDSs in high‐likelihood patients with negative initial imaging, potentially reducing unnecessary ERCPs.
- 3 July 2026
- Published by Wiley in Digestive Endoscopy
- Vol. 38 (7) , e70223
Endoscopic Reintervention Using a Slim Multi‐Hole Covered Metal Stent After Endoscopic Ultrasound‐Guided Hepaticogastrostomy
- 3 July 2026
- Published by Wiley in Digestive Endoscopy
- Vol. 38 (7) , e70223
Endoscopic Reintervention Using a Slim Multi‐Hole Covered Metal Stent After Endoscopic Ultrasound‐Guided Hepaticogastrostomy
- Open Access
Small‐Bowel Impaction Caused by Mechanical Interlocking Between Duodenal Metal and Biliary Plastic Stents
Duodenal self‐expandable metal stents (SEMS) are widely used to treat malignant gastric outlet obstruction (GOO). However, stent migration is a well‐known complication. We report a rare case of small‐bowel impaction caused by the migration of a duodenal SEMS with a biliary plastic stent (PS). A 78‐year‐old woman with pancreatic head cancer underwent biliary PS and duodenal SEMS placement for obstructive jaundice and GOO. At 4 months after initiating neoadjuvant chemotherapy, computed tomography revealed tumor shrinkage and improvement in duodenal stenosis; however, the SEMS and PS had migrated to the ileum. Double‐balloon enteroscopy was attempted; however, stent removal was unsuccessful because of mechanical interlocking and impaction. Therefore, a partial ileal resection was performed. Histopathological examination revealed transmural infiltration of inflammatory cells and abscess formation. If a duodenal SEMS migrates with a biliary PS, mechanical interlocking may occur, resulting in small‐bowel impaction. Clinicians should be aware of this rare complication and should consider careful follow‐up and timely intervention if stent migration is detected. Trial Registration : N/A
Open AccessSmall‐Bowel Impaction Caused by Mechanical Interlocking Between Duodenal Metal and Biliary Plastic Stents
Duodenal self‐expandable metal stents (SEMS) are widely used to treat malignant gastric outlet obstruction (GOO). However, stent migration is a well‐known complication. We report a rare case of small‐bowel impaction caused by the migration of a duodenal SEMS with a biliary plastic stent (PS). A 78‐year‐old woman with pancreatic head cancer underwent biliary PS and duodenal SEMS placement for obstructive jaundice and GOO. At 4 months after initiating neoadjuvant chemotherapy, computed tomography revealed tumor shrinkage and improvement in duodenal stenosis; however, the SEMS and PS had migrated to the ileum. Double‐balloon enteroscopy was attempted; however, stent removal was unsuccessful because of mechanical interlocking and impaction. Therefore, a partial ileal resection was performed. Histopathological examination revealed transmural infiltration of inflammatory cells and abscess formation. If a duodenal SEMS migrates with a biliary PS, mechanical interlocking may occur, resulting in small‐bowel impaction. Clinicians should be aware of this rare complication and should consider careful follow‐up and timely intervention if stent migration is detected. Trial Registration : N/A
- 14 May 2026
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 104 (4) , 677-678
Ultra-acute-onset arytenoid congestion during esophagogastroduodenoscopy
- 14 May 2026
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 104 (4) , 677-678
Ultra-acute-onset arytenoid congestion during esophagogastroduodenoscopy
- Open Access
High CD73 Expression Is Associated with Poor Prognosis in Biliary Tract Cancer Through Reduced Stromal Tumor-Infiltrating Lymphocytes
Background: Biliary tract cancer (BTC) is an aggressive malignancy with limited therapeutic options and a poor prognosis. CD73 is upregulated under hypoxic conditions and promotes tumor progression. However, its clinical role in BTC and interaction with tumor-infiltrating lymphocytes (TILs) remain unclear. This study aimed to elucidate the association between CD73 expression and prognosis in BTC, as well as its impact on the tumor microenvironment (TME) and TILs. Methods: This retrospective study included 100 patients who underwent curative BTC surgery at Hokkaido University Hospital between 2018 and 2023. Formalin-fixed tumor specimens were analyzed using DeepPathFinder™ (biomy Inc., Tokyo, Japan), an AI-based digital pathology platform enabling objective quantification of CD73 expression and lymphocyte infiltration within tumoral (T) and stromal (S) compartments. Immunohistochemistry for CD3, CD8, Foxp3, and CD163 was used to identify T-cell subsets and macrophages. Associations between CD73, TIL subsets, and overall survival (OS) were assessed using the Kaplan–Meier, Cox regression, and Spearman correlation analyses. Results: High T-CD73 expression was associated with shorter OS (hazard ratio [HR] = 1.97, p = 0.041), whereas S-CD73 showed no prognostic relevance. Conversely, high S-TIL density was correlated with improved survival (HR = 0.49, p = 0.032). T-CD73 expression was negatively correlated with stromal CD3+ and CD8+ T-cell densities, indicating selective suppression of stromal cytotoxic T-lymphocyte (CTL) infiltration. No significant correlations were observed between Foxp3+ T cells and CD163+ M2 macrophages. Conclusions: CD73 upregulation in tumor cells impairs stromal CTL and TIL activity, leading to a poor prognosis. Spatial distribution, rather than total TIL number, better reflects effective anti-tumor immunity.
Open AccessHigh CD73 Expression Is Associated with Poor Prognosis in Biliary Tract Cancer Through Reduced Stromal Tumor-Infiltrating Lymphocytes
Background: Biliary tract cancer (BTC) is an aggressive malignancy with limited therapeutic options and a poor prognosis. CD73 is upregulated under hypoxic conditions and promotes tumor progression. However, its clinical role in BTC and interaction with tumor-infiltrating lymphocytes (TILs) remain unclear. This study aimed to elucidate the association between CD73 expression and prognosis in BTC, as well as its impact on the tumor microenvironment (TME) and TILs. Methods: This retrospective study included 100 patients who underwent curative BTC surgery at Hokkaido University Hospital between 2018 and 2023. Formalin-fixed tumor specimens were analyzed using DeepPathFinder™ (biomy Inc., Tokyo, Japan), an AI-based digital pathology platform enabling objective quantification of CD73 expression and lymphocyte infiltration within tumoral (T) and stromal (S) compartments. Immunohistochemistry for CD3, CD8, Foxp3, and CD163 was used to identify T-cell subsets and macrophages. Associations between CD73, TIL subsets, and overall survival (OS) were assessed using the Kaplan–Meier, Cox regression, and Spearman correlation analyses. Results: High T-CD73 expression was associated with shorter OS (hazard ratio [HR] = 1.97, p = 0.041), whereas S-CD73 showed no prognostic relevance. Conversely, high S-TIL density was correlated with improved survival (HR = 0.49, p = 0.032). T-CD73 expression was negatively correlated with stromal CD3+ and CD8+ T-cell densities, indicating selective suppression of stromal cytotoxic T-lymphocyte (CTL) infiltration. No significant correlations were observed between Foxp3+ T cells and CD163+ M2 macrophages. Conclusions: CD73 upregulation in tumor cells impairs stromal CTL and TIL activity, leading to a poor prognosis. Spatial distribution, rather than total TIL number, better reflects effective anti-tumor immunity.
- Open Access
- 8 January 2026
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 58 (S 01) , E370-E371
Contrast-enhanced endoscopic ultrasound-guided additional ethanol ablation after early detection of occult residual pancreatic insulinoma
The usefulness of endoscopic ultrasound (EUS)-guided ethanol ablation (EUS-EA) for small non-functional pancreatic neuroendocrine neoplasms and insulinomas has been reported [1] [2]. Even when sufficient ablation appears achieved, additional ablation is sometimes required within 3–5 days [1]. However, additional treatment can be difficult when residual lesions are not identifiable on conventional EUS. We report a case with occult residual insulinoma after EUS-EA that was undetectable on conventional EUS but identified by contrast-enhanced EUS (CE-EUS), enabling additional ethanol ablation. A 57-year-old woman was referred for an insulinoma causing recurrent hypoglycemia. Contrast-enhanced computed tomography (CE-CT) showed a 10-mm tumor in the pancreatic tail with early enhancement ([Fig. 1]). EUS-EA was performed. The tumor was punctured with a 25-gauge needle filled with undiluted ethanol (99.5% v/v) without a stylet, and 1.7 mL was injected until the lesion became hyperechoic ([Fig. 2]). The needle was left in place for 1 minute and withdrawn. CE-CT 3 days later demonstrated an early-enhancing area at the lesion margin, suggestive of residual tumor ([Fig. 3]). As the patient continued occasional hypoglycemia, additional EUS-EA was planned. Conventional EUS showed a heterogeneous echo pattern, making localization difficult ([Fig. 4]). After intravenous perflubutane injection, the ablated area showed no enhancement, whereas the residual tumor became clearly visible on CE-EUS, allowing additional ethanol ablation with 1.0 mL ([Video 1]; [Fig. 5]). CE-CT 3 months later revealed no residual tumor, and no further hypoglycemic episodes were observed. Several reports have demonstrated the utility of CE-EUS for early evaluation of residual tumor after EUS-guided radiofrequency ablation of pancreatic neoplasms [3] [4], whereas, to our knowledge, no such reports exist for EUS-EA. Therefore, CE-EUS should be considered when residual tumor after EUS-EA is difficult to delineate. Treatment options for insulinomas include surgery, medical therapy, or minimally invasive approaches such as EUS-EA, which can be considered a less invasive alternative for selected small insulinomas. Endoscopy_UCTN_Code_TTT_1AS_2AD Endoscopy_UCTN_Code_TTT_1AS_2AI Article published online: 09 March 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 8 January 2026
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 58 (S 01) , E370-E371
Open AccessContrast-enhanced endoscopic ultrasound-guided additional ethanol ablation after early detection of occult residual pancreatic insulinoma
The usefulness of endoscopic ultrasound (EUS)-guided ethanol ablation (EUS-EA) for small non-functional pancreatic neuroendocrine neoplasms and insulinomas has been reported [1] [2]. Even when sufficient ablation appears achieved, additional ablation is sometimes required within 3–5 days [1]. However, additional treatment can be difficult when residual lesions are not identifiable on conventional EUS. We report a case with occult residual insulinoma after EUS-EA that was undetectable on conventional EUS but identified by contrast-enhanced EUS (CE-EUS), enabling additional ethanol ablation. A 57-year-old woman was referred for an insulinoma causing recurrent hypoglycemia. Contrast-enhanced computed tomography (CE-CT) showed a 10-mm tumor in the pancreatic tail with early enhancement ([Fig. 1]). EUS-EA was performed. The tumor was punctured with a 25-gauge needle filled with undiluted ethanol (99.5% v/v) without a stylet, and 1.7 mL was injected until the lesion became hyperechoic ([Fig. 2]). The needle was left in place for 1 minute and withdrawn. CE-CT 3 days later demonstrated an early-enhancing area at the lesion margin, suggestive of residual tumor ([Fig. 3]). As the patient continued occasional hypoglycemia, additional EUS-EA was planned. Conventional EUS showed a heterogeneous echo pattern, making localization difficult ([Fig. 4]). After intravenous perflubutane injection, the ablated area showed no enhancement, whereas the residual tumor became clearly visible on CE-EUS, allowing additional ethanol ablation with 1.0 mL ([Video 1]; [Fig. 5]). CE-CT 3 months later revealed no residual tumor, and no further hypoglycemic episodes were observed. Several reports have demonstrated the utility of CE-EUS for early evaluation of residual tumor after EUS-guided radiofrequency ablation of pancreatic neoplasms [3] [4], whereas, to our knowledge, no such reports exist for EUS-EA. Therefore, CE-EUS should be considered when residual tumor after EUS-EA is difficult to delineate. Treatment options for insulinomas include surgery, medical therapy, or minimally invasive approaches such as EUS-EA, which can be considered a less invasive alternative for selected small insulinomas. Endoscopy_UCTN_Code_TTT_1AS_2AD Endoscopy_UCTN_Code_TTT_1AS_2AI Article published online: 09 March 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- Open Access
DNMT3B Knockdown Enhances PARP Inhibitor Sensitivity in Biliary Tract Cancer Cells via Opioid Growth Factor Receptor-Mediated Homologous Recombination Impairment
Background: Biliary tract cancer (BTC) is an aggressive malignancy with poor prognosis and limited therapeutic options. Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated efficacy in tumors with homologous recombination repair (HRR) deficiency. However, actionable BRCA1/2 mutations are rare in BTC. Epigenetic modulation via DNA methyltransferase (DNMT) inhibition is a proposed strategy for inducing an HR-deficient (“BRCAness”) phenotype and thereby enhancing therapeutic response to PARP inhibitors. This study aimed to determine whether the DNMT inhibitor azacitidine (AZA) enhances the antitumor effects of the PARP inhibitor niraparib (NIR) and to identify molecular mechanisms underlying this interaction. Methods: Two BTC cell lines, TFK-1 and RBE, were treated with AZA and/or NIR or subjected to siRNA-mediated DNMT1, DNMT3A, or DNMT3B knockdown. Functional analyses included homologous recombination (HR) assays, flow cytometric evaluation of cell-cycle distribution and apoptosis, proliferation and survival assays, and IC50 determination. Whole-transcriptome RNA sequencing was performed to identify differentially expressed genes after AZA treatment or DNMT3B knockdown, followed by validation via qPCR and Western blotting. To explore epigenetic regulation, whole-genome bisulfite sequencing was performed on TFK-1 cells following DNMT3B knockdown. Results: AZA treatment decreased HR frequency in a dose-dependent manner and enhanced the sensitivity of BTC cells to NIR, as evidenced by increased apoptosis, suppressed proliferation, and reduced IC50 values. DNMT3B knockdown recapitulated these effects, establishing a causal relationship between DNMT3B suppression and disrupted HR repair. RNA sequencing identified opioid growth factor receptor (OGFR) as a commonly upregulated gene after DNMT3B knockdown. Functional validation showed that OGFR overexpression reduced HR activity, increased apoptosis, and enhanced NIR sensitivity. Contrarily, OGFR knockdown conferred relative resistance. Whole-genome bisulfite sequencing showed no significant CpG methylation changes at the OGFR promoter region, indicating that OGFR induction is mediated through DNMT3B-dependent transcriptional regulation rather than direct promoter demethylation. Conclusions: DNMT3B inhibition sensitizes BTC cells to PARP inhibitors by disrupting HR repair. OGFR was identified as a novel regulator of HR and PARP inhibitor sensitivity, controlled via noncanonical DNMT3B-dependent transcriptional mechanisms that operate independently of CpG methylation. These findings provide new mechanistic insights into the epigenetic control of DNA repair and support the rationale for combining DNMT and PARP inhibitors as a promising therapeutic strategy for BTC beyond genetically HR-deficient cases.
Open AccessDNMT3B Knockdown Enhances PARP Inhibitor Sensitivity in Biliary Tract Cancer Cells via Opioid Growth Factor Receptor-Mediated Homologous Recombination Impairment
Background: Biliary tract cancer (BTC) is an aggressive malignancy with poor prognosis and limited therapeutic options. Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated efficacy in tumors with homologous recombination repair (HRR) deficiency. However, actionable BRCA1/2 mutations are rare in BTC. Epigenetic modulation via DNA methyltransferase (DNMT) inhibition is a proposed strategy for inducing an HR-deficient (“BRCAness”) phenotype and thereby enhancing therapeutic response to PARP inhibitors. This study aimed to determine whether the DNMT inhibitor azacitidine (AZA) enhances the antitumor effects of the PARP inhibitor niraparib (NIR) and to identify molecular mechanisms underlying this interaction. Methods: Two BTC cell lines, TFK-1 and RBE, were treated with AZA and/or NIR or subjected to siRNA-mediated DNMT1, DNMT3A, or DNMT3B knockdown. Functional analyses included homologous recombination (HR) assays, flow cytometric evaluation of cell-cycle distribution and apoptosis, proliferation and survival assays, and IC50 determination. Whole-transcriptome RNA sequencing was performed to identify differentially expressed genes after AZA treatment or DNMT3B knockdown, followed by validation via qPCR and Western blotting. To explore epigenetic regulation, whole-genome bisulfite sequencing was performed on TFK-1 cells following DNMT3B knockdown. Results: AZA treatment decreased HR frequency in a dose-dependent manner and enhanced the sensitivity of BTC cells to NIR, as evidenced by increased apoptosis, suppressed proliferation, and reduced IC50 values. DNMT3B knockdown recapitulated these effects, establishing a causal relationship between DNMT3B suppression and disrupted HR repair. RNA sequencing identified opioid growth factor receptor (OGFR) as a commonly upregulated gene after DNMT3B knockdown. Functional validation showed that OGFR overexpression reduced HR activity, increased apoptosis, and enhanced NIR sensitivity. Contrarily, OGFR knockdown conferred relative resistance. Whole-genome bisulfite sequencing showed no significant CpG methylation changes at the OGFR promoter region, indicating that OGFR induction is mediated through DNMT3B-dependent transcriptional regulation rather than direct promoter demethylation. Conclusions: DNMT3B inhibition sensitizes BTC cells to PARP inhibitors by disrupting HR repair. OGFR was identified as a novel regulator of HR and PARP inhibitor sensitivity, controlled via noncanonical DNMT3B-dependent transcriptional mechanisms that operate independently of CpG methylation. These findings provide new mechanistic insights into the epigenetic control of DNA repair and support the rationale for combining DNMT and PARP inhibitors as a promising therapeutic strategy for BTC beyond genetically HR-deficient cases.
- 9 March 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (5) , 1042-1044
Panniculitis of the Lower Extremities Caused by Acute Deterioration of Autoimmune Pancreatitis
A 73‐year‐old female with type 1 autoimmune pancreatitis (AIP) presented with painful erythema on her lower extremities and elevated serum pancreatic enzyme levels. Her CT images revealed focal enlargement of the pancreatic tail with an increased density of the surrounding fatty tissue. Based on serum and CT findings, she was diagnosed as having acute deterioration of AIP. Skin biopsy of erythema revealed fat necrosis with ghost cells, calcification, and inflammatory infiltration, consistent with pancreatic panniculitis. Increasing the prednisolone dose to 25 mg/day promptly ameliorated her symptoms and normalized her enzyme levels.Pancreatic panniculitis is a rare complication of pancreatitis characterized by painful subcutaneous nodules and fat necrosis. Although it has been reported in association with conditions such as pancreatic cancer and chronic pancreatitis, its occurrence in AIP has not been documented. This case highlights pancreatic panniculitis as a potential complication of AIP for the first time.
- 9 March 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (5) , 1042-1044
Panniculitis of the Lower Extremities Caused by Acute Deterioration of Autoimmune Pancreatitis
A 73‐year‐old female with type 1 autoimmune pancreatitis (AIP) presented with painful erythema on her lower extremities and elevated serum pancreatic enzyme levels. Her CT images revealed focal enlargement of the pancreatic tail with an increased density of the surrounding fatty tissue. Based on serum and CT findings, she was diagnosed as having acute deterioration of AIP. Skin biopsy of erythema revealed fat necrosis with ghost cells, calcification, and inflammatory infiltration, consistent with pancreatic panniculitis. Increasing the prednisolone dose to 25 mg/day promptly ameliorated her symptoms and normalized her enzyme levels.Pancreatic panniculitis is a rare complication of pancreatitis characterized by painful subcutaneous nodules and fat necrosis. Although it has been reported in association with conditions such as pancreatic cancer and chronic pancreatitis, its occurrence in AIP has not been documented. This case highlights pancreatic panniculitis as a potential complication of AIP for the first time.